News

According to Pfizer, the combination of the consumer healthcare businesses had registered global sales of nearly $12.7bn in 2017. GSK said that the combination will comprise two portfolios

Under the terms of the agreement, Innovare will use DelSiTech’s technology on its peptide membrane fusion inhibitor, targeting the envelope protein of human immunodeficiency virus-1 (HIV-1). DelSiTech is

Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) indicated to treat patients who use hemodialysis or peritoneal dialysis. It will help induce coordinated erythropoiesis, increase red blood

MP0310 is a preclinical molecule designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via

The trial was held in patients who previously experienced inadequate responses to two to four classes of preventive treatments. In the study of 838 patients, including those who

VE303 is claimed to be the first drug featuring a rationally-defined bacterial consortium to advance to phase 2 study. The earlier announced phase 1a/1b study showed rapid, durable,

Alvotech and Fuji Pharma recently announced an exclusive agreement for development and commercialization of biosimilars in Japan. Fuji´s investment into Alvotech further strengthens the partnership between the companies

The partnership between C4XD and the Horizon Discovery intends to assess synthetic lethal oncology targets identified by the latter’s CRISPR-Cas9 technology. C4XD will apply its 4D shape-based chemistry

Zirabev is a monoclonal antibody for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent non-small cell lung cancer